2019 Rosenman Innovator, Bloomlife, has raised $12.2M in Series A funding to advance its maternal health technology platform. The company recently received FDA clearance for its wearable MFM-Pro device, which monitors maternal and fetal heart rates. Bloomlife’s holistic approach integrates remote care solutions for hypertension, diabetes, mental health, and social determinants of health into a centralized platform that improves access and outcomes for mothers.
From the press release:
Bloomlife, a leader in maternal health technology, has successfully raised $12.2 million in a Series A funding round, marking a significant step forward in its mission to advance maternal healthcare. The funding round was led by Kapor Capital and European investor Noshaq and included follow-on investments from existing backers such as RH Capital, 15th Rock Ventures, The Grove Foundation, Stardust Equity, and Lean Square.
The investment follows Bloomlife’s recent FDA clearance for its MFM-Pro device, a wearable that monitors both maternal and fetal heart rates. The newly secured funds will support Bloomlife’s commercial expansion and the development and FDA clearance of a second proprietary device, further solidifying the company’s position in the rapidly growing maternal health technology sector.
Eric Dy, Ph.D., Co-Founder and CEO of Bloomlife, commented on the evolving landscape of maternal healthcare in an interview: “The healthcare industry is increasingly receptive to reevaluating how maternal care is delivered. The shifts we’ve seen, particularly following the COVID-19 pandemic, highlight the need for more efficient, accessible, and patient-centered care models.”